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1810–1.ReplyDiagnosis and Treatment of Obstructive
Sleep Apnea Is Key to Achieving Optimal
Results After Catheter Ablation of
Atrial FibrillationThe association between obstructive sleep apnea (OSA) and car-
diovascular morbidity is well established (1,2). In particular, OSA
has been shown to potentiate atrial ﬁbrillation (AF) substrate in
both animal and human studies (3–7). Our study not only de-
monstrated that OSA adversely affects the results of AF ablation,
but also highlighted the beneﬁcial effect of OSA treatment on
AF ablation outcome in this patient population (8).
Wilcox and colleagues have articulately argued that OSA is
an underdiagnosed disease, likely to coexist in a signiﬁcant pro-
portion of patients with AF. They drew our attention to the current
framework with which we deﬁne OSA and subsequently use to
screen patients. We agree that the current criteria overemphasize
respiratory symptomatology and daytime somnolence, which may
affect a minority of patients with OSA (9–11). The traditional focus
on these symptoms oversimpliﬁes the clinical proﬁle of patients with
sleep apnea and thus underestimates its pronounced cardiovascular
impact, which may be the heralding symptom.
Threshold criteria for OSA testing in patients with AF should
probably be lowered, considering the higher pre-test probability
in this patient population. Until new criteria are formalized, we
should promote awareness of the association between OSA and
AF. Not only is timely identiﬁcation of OSA in AF patients
important in optimizing AF management, but it may mitigate
other deleterious cardiovascular effects.Adam S. Fein, MD
Alexei Shvilkin, MD, PhD
*Elad Anter, MD
*Division of Cardiology
Harvard Thorndike Electrophysiology Institute
Beth Israel Deaconess Medical CenterHarvard Medical School
185 Pilgrim Road, W/BA4
Boston, Massachusetts 02215
E-mail: eanter@bidmc.harvard.edu
http://dx.doi.org/10.1016/j.jacc.2013.10.045
Please note: Dr. Anter has received research grants from Biosense Webster and
Rhythmia Medical. Drs. Fein and Shvilkin have reported that they have no re-
lationships relevant to the contents of this paper to disclose.REFERENCES
1. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and
cardiovascular disease. J Am Coll Cardiol 2003;41:1429–37.
2. Valham F, Mooe T, Rabben T, Stenlund H, Wiklund U, Franklin KA.
Increased risk of stroke in patients with coronary artery disease and sleep
apnea: a 10-year follow-up. Circulation 2008;118:955–60.
3. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive
sleep apnea: implications for atrial ﬁbrillation. Heart Rhythm 2012;9:
321–7.
4. Otto ME, Belohlavek M, Romero-Corral A, et al. Comparison of
cardiac structural and functional changes in obese otherwise healthy
adults with versus without obstructive sleep apnea. Am J Cardiol 2007;
99:1298–302.
5. Romero-Corral A, Somers VK, Pellikka PA, et al. Decreased right and
left ventricular myocardial performance in obstructive sleep apnea.
Chest 2007;132:1863–70.
6. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic
neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:
1897–904.
7. Monahan K, Storfer-Isser A, Mehra R, et al. Triggering of nocturnal
arrhythmias by sleep-disordered breathing events. J Am Coll Cardiol
2009;54:1797–804.
8. Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep
apnea reduces the risk of atrial ﬁbrillation recurrence after catheter
ablation. J Am Coll Cardiol 2013;62:300–5.
9. Wilcox I, Semsarian C. Obstructive sleep apnea a respiratory syndrome
with protean cardiovascular manifestations. J Am Coll Cardiol 2009;54:
1810–2.
10. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The
occurrence of sleep-disordered breathing among middle-aged adults.
N Engl J Med 1993;328:1230–5.
11. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and
mortality: eighteen-year follow-up of the wisconsin sleep cohort. Sleep
2008;31:1071–8.Effect of Ivabradine on
Heart Failure With
Preserved Ejection FractionWe read with great interest the paper by Kosmala et al. (1) in which
they report the increased exercise capacity associated with an im-
proved left ventricular (LV) ﬁlling pressure in patients with heart
failure with preserved ejection fraction (HFpEF) treated with
ivabradine. In addition to the mechanisms elegantly discussed by the
authors, we would like to point out other potential important con-
tributors to the observed effect.
Heart rate (HR) is one of the major diastolic function de-
terminants. Indeed, an increase in HR may shorten the diastole
duration, precluding myocardial relaxation from being complete,
and resulting in increased ﬁlling pressures. This may be particularly
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609relevant in the setting of slower relaxation, as may be observed in
HFpEF patients. Slow incomplete relaxation can be induced by
excessive afterload to such an extent that it leads to marked increases
in ﬁlling pressures.When the ejection fraction is preserved, the effect
of afterload is particularly evident and signiﬁcantly exacerbated at
higher pre-loads (2). Moreover, in contrast to normal hearts, the
myocardium of heart failure patients may exhibit a ﬂat or negative
myocardial relaxation velocity to HR relationship, even at a lower
range of HR (3). Consequently, lowering the HR during early ex-
ercise would prevent the clinical expression of this HR-dependent
relaxation impairment.
Finally, as Reil et al. (4) recently showed, ivabradine decreases
arterial elastance through an enhancement of arterial compliance
and a reduction in HR. This reduction in global LV afterload
could also contribute to the short-term increase in exercise
tolerance described in the ivabradine-treated HFpEF patient
group.
The absence of a negative lusitropic pharmacological action and
the ability to modulate these diastolic function determinants (HR
and afterload) make ivabradine a mechanistically very attractive
drug in HFpEF treatment. Future clinical trials will give the critical
verdict.Mário Santos, MD
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Cardiol 2013;62:1977–85.ReplyEffect of Ivabradine on Heart Failure
With Preserved Ejection FractionWe appreciate the interest of Drs. Santos and Leite-Moreira in our
work (1). We completely agree with their comments regarding the
importance of heart rate (HR) as a contributor to diastolic function.
Ivabradine has a unique position as a negative chronotrope that is
not a negative inotrope. Indeed, the rationale for treatment with
ivabradine in our study was to avoid the reduction in the duration
of diastole that follows from an increase in HR.
Disturbances in the relationship between HR and myocardial
relaxation in failing hearts might represent another aspect supporting
the use of If channel inhibition in this context. Although ivabradine
hasmultiple effects, a direct effect onmyocardial relaxationmay be an
important beneﬁt. In addition, the potential effects of ivabradine on
arterial compliance and afterload in heart failure with preserved
ejection fraction (HFpEF) require, in our view, further evaluation.
The patient selection in our study was focused on patients in
whom exertional dyspnea develops, which is related in part to
shortening of diastole during tachycardia. The clinical effects of
ivabradine are being investigated in a large multicenter study, but
it is likely that this will involve a heterogeneous group. We would
like to draw the attention of readers to the need for studying
well-characterized subgroups of the very heterogeneous entity of
heart failure with preserved ejection fraction.*Thomas H. Marwick, MD, PhD
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